SUMMARY A controlled trial of azathioprine treatment of steroid-responsive frequent-relapsing nephrotic syndrome of childhood failed to show a therapeutic effect on the stability of remission after withdrawal of corticosteroid treatment. Cyclophosphamide has been shown to be effective in preventing relapse of steroid-responsive nephrotic syndrome of childhood We thought that their use of intermittent prednisone militated against detection of a therapeutic effect of azathioprine because of the low rate of relapse in the placebo group. In view of the anxiety about the side effects of cyclophosphamide (Fairley, et al., 1972) , we felt that it was necessary to re-examine the possibility that azathioprine might enhance the stability of remission in those patients.
Cyclophosphamide has been shown to be effective in preventing relapse of steroid-responsive nephrotic syndrome of childhood . However, a similar significant effect was not observed by Abramowicz et al. (1970) , in a doubleblind trial of azathioprine. This drug was administered in a dosage of 60 mg/M2 surface area per day for 6 months to steroid-responsive nephrotic children, maintained on intermittent prednisone. This study did show, however, that there was a nonsignificant trend toward fewer relapses in the treated group. We thought that their use of intermittent prednisone militated against detection of a therapeutic effect of azathioprine because of the low rate of relapse in the placebo group. In view of the anxiety about the side effects of cyclophosphamide (Fairley, et al., 1972) , we felt that it was necessary to re-examine the possibility that azathioprine might enhance the stability of remission in those patients.
Patients and methods
Diagnostic criteria and definitions have been previously published . Albumin was measured immunochemically and its excretion in random urine samples was expressed as the albumin/creatinine concentration ratio (Ua/Uc) .
Children under 14 years of age with steroidresponsive frequent-relapsing nephrotic syndrome who had previously relapsed on at least 0 -2 mg/kg body weight of prednisolone on alternate days were included in the trial when they had been in prednisolone-maintained remission for at least 2 weeks. Some of the children who had previously been We then considered what the position would be if of the remaining 8 children all the controls relapsed and all the treated patients remained in remission. Even if that had happened, the difference of frequency of relapse in the two groups would not have been significant, so the trial was stopped.
Discussion
Our data are similar to those of Abramowicz et al. (1970) and fail to show a therapeutic effect of azathioprine in preventing relapse of steroid-responsive nephrotic syndrome. It is of interest that cyclophosphamide should be effective and azathioprine not, since both drugs have immunosuppressive characteristics; but they act in different ways, cyclophosphamide being an alkylating agent and azathioprine an antimetabolite. There is now considerable evidence that this disease has an immune basis (Thomson et al., 1976) but the mechanism of damage is not known and so the effect of cyclophosphamide may not be immunosuppressive. Another possibility is that the dose or duration of azathioprine therapy was inadequate. But at doses of azathioprine greater than 2*5 mg/kg per day dose-related toxicity becomes apparent, the most serious being thrombocytopenia and a reduced white cell count. Our study provides no support for a change from cyclophosphamide to azathioprine to avoid the risk of gonadal toxicity reported for cyclophosphamide (Fairley et al., 1972) . 
